Elite Pharmaceuticals (ELTP) just posted its Q3 2026 numbers, with revenue of US$31.6 million, basic EPS of US$0.017, and net income of US$18.6 million, while on a trailing twelve month basis revenue sits at US$140.1 million and EPS at US$0.040. Over the past few quarters, the company has seen revenue move between US$14.4 million and US$40.2 million per quarter, with basic EPS ranging from a loss of US$0.010 to a profit of US$0.018, and trailing twelve month EPS shifting from a loss of US$0.017 to a profit of US$0.041. Taken together, the latest results describe a business where profitability has turned a corner and margins are now a key focus for investors assessing how durable this earnings profile might be.

See our full analysis for Elite Pharmaceuticals.

With the headline figures in place, the next step is to set these results against the widely discussed narratives around Elite Pharmaceuticals to see which views the numbers support and which they call into question.

TTM Net Income Reaches US$43.4 Million

• On a trailing twelve month basis, Elite Pharmaceuticals reported net income of US$43.4 million and basic EPS of US$0.041, compared with trailing revenue of US$140.1 million over the same period.
• For investors who focus on Elite becoming profitable, what stands out is that trailing EPS of US$0.041 and five year average earnings growth of 6.6% per year sit alongside a high level of non cash components in those earnings. This means investors who like the profit turnaround still need to check how much of that US$43.4 million actually comes through in cash flows and how that affects the durability of the current profit trend.

Quarterly Profit Swings Around New Product Activity

• Across recent quarters, net income moved from a loss of US$10.9 million in Q3 2025 to a loss of US$11.0 million in Q2 2025, then to a loss of US$5.9 million in Q1 2026 when 1 product was launched, before turning to profits of US$17.0 million in Q4 2025, US$13.7 million in Q2 2026 and US$18.6 million in Q3 2026 as products in pre registration rose from 2 to 3.
• Critics highlight that the recent shift to profits could prove fragile, and the pattern of losses and profits across 2025 and 2026 gives them some support. At the same time, the move from trailing EPS of a loss of US$0.017 in Q3 2025 to a profit of US$0.041 by Q3 2026, alongside product launches and preparations for registration, is also why more optimistic investors point to a business that has started to turn prior losses into positive earnings, even if the exact quarterly path has been uneven.

P/E of 10.1x and DCF Fair Value Gap

• Elite Pharmaceuticals is reported on a trailing P/E of 10.1x, which is below the US Pharmaceuticals industry average of 20.1x and a peer average of 25.8x, while the current share price of US$0.41 sits well below a DCF fair value of about US$2.59 per share.
• This creates some tension for a bearish narrative that argues the stock might be expensive despite recent profits. The current price of US$0.41 is described as trading about 84.3% below the DCF fair value of US$2.59 and at a P/E that is lower than both industry and peers. However, the same analysis also flags a major risk around high non cash earnings, so investors need to weigh the apparent discount on both the P/E and DCF fair value against the question of how closely reported EPS of US$0.041 over the last year tracks the company’s actual cash generating ability.

Curious how other investors tie these profit trends and valuation gaps together for Elite Pharmaceuticals, and where they think the story goes next, you can see what the community is saying in 📊 Read the what the Community is saying about Elite Pharmaceuticals.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Elite Pharmaceuticals's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of risks and rewards feels finely balanced, it may be a good time to review the facts yourself and act promptly. To see how other investors are weighing the upsides and concerns around Elite Pharmaceuticals, take a closer look at the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Elite Pharmaceuticals relies heavily on non cash earnings, with profits moving between losses and gains across recent quarters, which raises questions about how durable its current profitability really is.

If that earnings volatility and reliance on accounting items makes you uneasy, you might prefer checking companies in 80 resilient stocks with low risk scores that score better on stability and risk today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.